Dr. Yu Discusses the Utility of GTx-758 in mCRPC

Partner | Cancer Centers | <b>SCCA</b>

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in metastatic castration-resistant prostate cancer (mCRPC).

GTx-758 is a selective estrogen receptor alpha agonist that potentially has multiple mechanisms of action, including upregulating sex hormone binding globulin (SHBG) and lowering free testosterone levels.

In this trial, patients with mCRPC being treated with leuprorelin (Lupron) with low testosterone received low-dose (125 mg per day) GTx-758. These patients saw upregulated SHBG and decreased free testosterone levels, which translated into PSA declines. Researchers plan to analyze GTx-758 at 250 mg per day.